| % | Percentage |
| °C | Degrees Celsius |
| < | Less than |
| > | Greater than |
| 145-2C11 | Mouse ati-CD3 antibody |
| 2-DG | 2-Deoxy-D-glucose; glucose analog |
| 3D | three dimensional |
| 4-1BB | Costimulatory Receptor |
| α | alpha |
| β | beta |
| δ | delta |
| ε | epsilon |
| γ | gamma |
| ζ | zeta |
| αβ | alpha-beta TCR chains |
| γδ | gamma-delta TCR chains |
| δε | delta-epsilon CD3 subunit |
| γε | gamma-epsilon CD3 subunit |
| ζζ | zeta-zeta CD3 subunit |
| ADCC | Antibody-dependent cellular cytotoxicity |
| AP-1 | Activator protein; key transcription factor involved in T cell activation |
| APC | Antigen Presenting Cell |
| aPD-1 | Anti- PD-1 antibody; immune checkpoint blockade |
| aPDL-1 | Anti- PD-L1 antibody; immune checkpoint blockade |
| AX-024 | T cell inhibitor |
| BCMA | B-cell maturation antigen; Tumor associated antigen in hematological |
| BCR | B Cell Receptor, expressed on B cells |
| BiTE | Bispecific T Cell Engager; CD3Ab-TAA bispecific antibody |
| BRS | Basic-Rich Stretch; signaling motif in CD3/TCR subunits |
| Ca2+ | Calcium ions; released upon T cell activation |
| CAR T cells | Chimeric Antigen Receptor T cells; Modified T Cell based cancer immunotherapy |
| CD123 | Tumor associated antigen in hematological cancers |
| CD19 | Tumor associated antigen in hematological cancers |
| CD20 | Tumor associated antigen in hematological cancers |
| CD27 | Tumor associated antigen in hematological cancers |
| CD28 | Costimulatory Receptor |
| CD3 | Cd3 signalling subunit of the CD3-TCR complex on T cells |
| CD3+ | CD3 expressing |
| CD33 | Tumor associated antigen in hematological cancers |
| CD38 | Tumor associated antigen in hematological cancers |
| CD39 | Enzyme that converts ATP to ADP; ATP/adenosine pathway |
| CD3ɛ−/− | CD3 knock out |
| CD3-TCR | CD3-T Cell Receptor complex expressed on T Cells, composed of 1:1:1:1 ratio TCRαβ:CD3γε:CD3δε:CD3ζζ subunits |
| CD3δ | CD3 delta |
| CD3ε | CD3 epsilon |
| CD3γ | CD3 gamma |
| CD3ζ | CD3 zeta |
| CD3γε | Gamma-Epsilon heterodimeric subunit of the TCR/CD3 receptor complex |
| CD3δε | Delta-Epsilon heterodimeric subunit of the TCR/CD3 receptor complex |
| CD3ζζ | Zeta-Zeta homodimeric subunit of the TCR/CD3 receptor complex |
| CD4+ | CD4+ Helper T cell |
| CD40 | Costimulatory Receptor |
| CD43 | Protein tyrosine phosphatase that favors dephosphrylation of ITAMs |
| CD45 | Protein tyrosine phosphatase that favors dephosphrylation of ITAMs |
| CD47 | “Don’t eat me” signal expressed on tumor cells to prevent phagocytosis by macrophages |
| CD69 | Early T cell activation marker |
| CD73 | Enzyme that converts AMP to Adenosine; ATP/adenosine pathway |
| CD79αβ | Signalling subunit of the B Cell Receptor |
| CD8+ | CD8+ Cytotoxic T cell |
| CDC | complement-dependent cytotoxicity |
| CDRs | Complementarity-determining regions on T cells; involved in pMHC binding |
| CEA | Carcinoembryonic antigen; a type of tumor associated antigen |
| CNS | Central Nervous System |
| CRISPR/Cas9 | clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9; genomic engineering technique |
| CTLA-4 | Negative regulator of the immune response; Exhaustion marker on T cells |
| DAG | Diacylglycerol kinase involved in T cell activation signaling |
| DGKα | Diacylglycerol Kinase Alpha |
| DLL3 | Delta-like ligand 3; tumor associated antigen in neuroendocrine tumors |
| DNA | Deoxyribonucleic acid; Double stranded nucleic acid composed of the bases A, T, G and C |
| EAE | Experimental autoimmune encephalomyelitis |
| EGFRviii | Epidermal growth factor receptor variant III; tumor associated antigen in glioblastoma |
| EM | Electron Microscopy |
| EpCAM | Epithelial Cell Adhesion Molecule; tumor associated antigen |
| Fab | Antigen-binding fragment on antibody |
| Fc | Fragment crystallizable; Antigen non-binding fragment on antibody |
| FDA | U.S. Food and Drug Administration |
| FYN | src superfamily protein tyrosine kinases involved in ITAM phosphorylation |
| G4.18 | Anti-CD3 antibody |
| GMP | Good manufacturing practice; production quality regulations for clinical products and therapies |
| gp100 | Cognate peptide for PMEL T cells |
| HCV | Hepatitis C Virus |
| HER-2 | Human epidermal growth factor receptor 2; tumor associated antigen in breast cancers |
| HIF1-α | Hypoxia-inducible factor 1-alpha; key transcription factor that drives hypoxia |
| HLA | Human leukocyte antigens |
| IBD | inflammatory bowel disease |
| ICB | Immune Checkpoint Blocakde |
| ICOS | Inducible T-cell COStimulator; Costimulatory Receptor |
| IFN-γ | Interferon Gamma; T cell activation cytokine |
| IL-10 | Interleukin-10; anti-inflammatory cytokine |
| ImmTAC | Immune mobilizing monoclonal T-cell receptors against cancer |
| IP3 | Inositol trisphosphate |
| ITAM | Immunoreceptor tyrosine-based activation motif; involved in activation of T cells |
| lL-2 | Iinterleukin-2; T cell activation cytokine |
| LCK | src superfamily protein tyrosine kinases involved in ITAM phosphorylation |
| LIGS | Ligand-Guided Selection; a type of modified SELEX |
| mAb | Monoclonal antibody |
| MHC | Major Histocompatibility Complex; proteins involved in self-discrimination |
| miRNAs | microRNA; non-coding ssRNA molecule |
| MS | Multiple Sclerosis |
| MUC16 | Mucin 16; tumor associated antigen |
| NASH | nonalcoholic steatohepatitis |
| NCK | Non-catalytic region of tyrosine kinase; second messenger in T cell signalling |
| NFAT | Nuclear factor of activated T-cells; key transcription factor involved in T cell activation |
| NF-κB | Nuclear Factor kappa-light-chain-enhancer of activated B cells; key transcription factor involved in T cell activation |
| nM | Nanomolar |
| NOD | Nucleotide oligomerization domain |
| NSCLC | Non-small-cell lung carcinoma |
| OKT3 | Human Anti-CD3 antibody |
| OX-40 | Costimulatory Receptor |
| PD-1 | Programmed cell death protein 1; negative regulator of the immune response; Exhaustion marker on T cells |
| PDL-1 | Programmed death-ligand 1; negative regulator of the immune response |
| PLC | Phospholipase C; second messenger in T cell activation signaling |
| PLP139–151 EAE | PLP139–151 peptide-induced Experimental autoimmune encephalomyelitis |
| pMHC | Peptide-Major Histocompatibility Complex; cognate ligand for the T cell Receptor |
| PRS | Proline-Rich Stretch; signaling motif in CD3/TCR subunits |
| PSMA | Prostate-Specific Membrane Antigen; tumor associated antigen in prostate cancer |
| pSMAC | Peripheral supramolecular activation complex; macromolecular structure of TCRs in activated T cells |
| PTPN2 | Protein tyrosine phosphatase non-receptor type 2 |
| PTPN22 | Protein tyrosine phosphatase non-receptor type 22 |
| RAG1/2 | Recombination-activating gene 1/2 |
| Ras | Rat sarcoma virus protein; small GTPase |
| RNA | Riboxynucleic Acid; single stranded oligonucleotide containing the bases Adenine, Guanine, Uracil and Cytosine. |
| scFvs | Single Chain Variable Fragment; fusion protein of heavy and variable chains of the antigen binding arm of an antibody |
| SCID | Severe combined immunodeficiency |
| SELEX | Systematic Evolution of Ligands by Exponential Evolution; the process through which aptamers are identified |
| SH.3 | Src Homology 3 (SH3) domains; signaling motif present in protein tyrosine kinases |
| SHP1 | Src homology region 2 domain-containing phosphatase-1 |
| siRNAs | Small interfering RNA; non-coding RNA used to silence genes |
| SJL/J | Swiss Jim Lambert EAE mice |
| Src | src superfamily protein tyrosine kinases involved in ITAM phosphorylation |
| SSTR2 | Somatostatin receptor 2; Tumor associated antigen in pancreatic cancer |
| TCR | T Cell Receptor; expressed on T cells |
| TCR-CD3 | CD3-T Cell Receptor complex expressed on T Cells, composed of 1:1:1:1 ratio TCRαβ:CD3γε:CD3δε:CD3ζζ subunits |
| TCR α-β | alpha beta T Cell |
| TCR-scFv | fusion protein containing a TCR and a single chain variable fragment |
| TCRα | alpha chain of the TCR |
| TCRβ | beta chain of the TCR |